Close



Apr 23, 2024 09:01AM
Apr 23, 2024 09:00AM
Mar 19, 2024 09:00AM
Mar 6, 2024 08:45AM
Mar 6, 2024 08:45AM
Feb 15, 2024 08:00AM
Feb 13, 2024 12:00PM CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
Feb 9, 2024 08:30AM
Feb 9, 2024 08:30AM
Feb 6, 2024 09:00AM
Dec 22, 2023 08:00AM
Dec 4, 2023 08:30AM
Nov 20, 2023 04:15PM
Nov 16, 2023 08:30AM CEL-SCI Corp (CVM) Prices 2.49M Share Offering at $2/sh
Nov 16, 2023 08:30AM
Oct 30, 2023 09:21AM
Oct 30, 2023 09:20AM
Oct 24, 2023 08:00AM
Oct 23, 2023 09:15AM
Oct 19, 2023 08:00AM
Oct 5, 2023 08:45AM CEL-SCI Corp (CVM) Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
Oct 5, 2023 08:45AM
Sep 26, 2023 09:00AM
Aug 11, 2023 08:00AM
Jul 20, 2023 11:36AM
Jul 18, 2023 04:46AM
Jul 17, 2023 09:23PM
Jul 17, 2023 05:23PM After-hours movers: Masimo sinks on Q2 warning, Pinterest gains on upgrade
Jul 17, 2023 04:05PM
Jul 17, 2023 04:05PM
Jul 14, 2023 09:15AM
Jul 11, 2023 08:45AM
Jul 11, 2023 08:45AM
Jun 22, 2023 10:19AM
May 15, 2023 09:00AM Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
May 12, 2023 04:30PM
Apr 28, 2023 04:17AM
Apr 27, 2023 09:12PM
Apr 19, 2023 09:01AM
Apr 19, 2023 09:00AM
Mar 8, 2023 09:05AM
Mar 8, 2023 09:00AM CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
Mar 3, 2023 09:00AM
Feb 15, 2023 09:00AM
Dec 28, 2022 09:00AM
Nov 22, 2022 09:00AM
Oct 17, 2022 08:50AM
Oct 17, 2022 08:50AM
Sep 12, 2022 09:01AM CEL-SCI Corp (CVM) Presents Additional Phase 3 Data
Sep 12, 2022 09:00AM

251,657 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All